Black Swift Group LLC Takes Position in Exact Sciences Co. (NASDAQ:EXAS)

Black Swift Group LLC purchased a new position in Exact Sciences Co. (NASDAQ:EXAS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 3,000 shares of the medical research company’s stock, valued at approximately $204,000.

Several other hedge funds have also made changes to their positions in EXAS. Chicago Partners Investment Group LLC increased its stake in shares of Exact Sciences by 1.7% in the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock valued at $651,000 after purchasing an additional 158 shares during the period. Amalgamated Bank increased its position in Exact Sciences by 2.7% in the 2nd quarter. Amalgamated Bank now owns 10,937 shares of the medical research company’s stock valued at $462,000 after acquiring an additional 284 shares during the period. Midwest Professional Planners LTD. raised its stake in Exact Sciences by 12.3% during the 1st quarter. Midwest Professional Planners LTD. now owns 3,088 shares of the medical research company’s stock valued at $213,000 after acquiring an additional 339 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Exact Sciences by 92.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after acquiring an additional 340 shares during the period. Finally, Huntington National Bank grew its stake in shares of Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after purchasing an additional 352 shares in the last quarter. Institutional investors own 88.82% of the company’s stock.

Insider Buying and Selling at Exact Sciences

In other news, CEO Kevin T. Conroy purchased 19,500 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was bought at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the purchase, the chief executive officer now directly owns 1,074,191 shares of the company’s stock, valued at approximately $55,159,707.85. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the firm’s stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the transaction, the executive vice president now directly owns 12,758 shares in the company, valued at $893,060. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin T. Conroy purchased 19,500 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were bought at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the purchase, the chief executive officer now owns 1,074,191 shares in the company, valued at $55,159,707.85. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.36% of the company’s stock.

Exact Sciences Stock Down 2.7 %

Shares of EXAS traded down $1.39 during trading hours on Thursday, reaching $49.34. The company’s stock had a trading volume of 212,578 shares, compared to its average volume of 2,635,294. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The firm has a market cap of $9.13 billion, a price-to-earnings ratio of -43.36 and a beta of 1.27. The company has a 50 day moving average of $66.22 and a two-hundred day moving average of $56.30. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The company had revenue of $708.66 million during the quarter, compared to analysts’ expectations of $716.80 million. The company’s revenue for the quarter was up 12.8% on a year-over-year basis. As a group, research analysts predict that Exact Sciences Co. will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Citigroup cut their price objective on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Benchmark reduced their price target on shares of Exact Sciences from $67.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. TD Cowen lowered their price objective on shares of Exact Sciences from $90.00 to $82.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Stifel Nicolaus dropped their target price on Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, Raymond James reaffirmed a “market perform” rating on shares of Exact Sciences in a research note on Thursday, September 26th. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $74.47.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.